Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCDPHP Perjeta Medicaid Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentCapital District Physicians' Health Plan (CDPHP)Policy N/A

    Medicaid Coverage Policy for Perjeta (pertuzumab) Injection

    Customize your policy alerts

    Sign up for all cdphp policy alerts

    Know when cdphp releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicaid coverage of Perjeta (pertuzumab) injection for specified HER2-positive breast cancer indications, including metastatic, neoadjuvant, and adjuvant treatment.

    Policy Summary
    PayerCapital District Physicians' Health Plan (CDPHP)
    PolicyMedicaid Coverage Policy for Perjeta (pertuzumab) Injection
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionPerjeta does not require prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Covered clinical indications
    J9306HCPCS code
    50242-0145-01NDC
    Not requiredPrior authorization
    420 mg/14 mLVial strength

    Covered Indications

    Covered Indications

    Perjeta is covered when the patient meets ANY ONE of the following listed indications:

    Listed indications

    • Metastatic breast cancer: HER2-positive metastatic breast cancer treated in combination with trastuzumab and docetaxel in a patient who has not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
    • Neoadjuvant breast cancer: HER2-positive, locally advanced, inflammatory, or early-stage breast cancer treated neoadjuvantly in combination with trastuzumab and chemotherapy, with early-stage disease greater than 2 cm in diameter or node positive, as part of a complete treatment regimen for early breast cancer.> 2 cm in diameter or node positive
    • Adjuvant breast cancer:
    Policy Summary
    PayerCapital District Physicians' Health Plan (CDPHP)
    PolicyMedicaid Coverage Policy for Perjeta (pertuzumab) Injection
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionPerjeta does not require prior authorization.
    SourceLink
    On This Page
    Covered IndicationsInitial TherapyCovered CodesClinical Background

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    HER2-positive early breast cancer treated adjuvantly in combination with trastuzumab and chemotherapy in a patient at high risk of recurrence.
    High risk of recurrence

    Initial Therapy

    Initial Therapy

    Initial treatment is covered when ANY ONE of the following indications applies:

    Initial covered indications

    • Metastatic breast cancer: HER2-positive metastatic breast cancer treated in combination with trastuzumab and docetaxel in a patient who has not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
    • Neoadjuvant breast cancer: HER2-positive, locally advanced, inflammatory, or early-stage breast cancer treated neoadjuvantly in combination with trastuzumab and chemotherapy, with early-stage disease greater than 2 cm in diameter or node positive, as part of a complete treatment regimen for early breast cancer.> 2 cm in diameter or node positive
    • Adjuvant breast cancer: HER2-positive early breast cancer treated adjuvantly in combination with trastuzumab and chemotherapy in a patient at high risk of recurrence.High risk of recurrence

    Covered Codes

    ICD10 Diagnosis CodesICD-10Covered
    C50.011-C50.019ICD10 diagnosis code range
    C50.111-C50-119ICD10 diagnosis code range
    C50.211ICD10 diagnosis code
    C50.219ICD10 diagnosis code
    C50.311-C50.319ICD10 diagnosis code range
    C50.411-C50.419ICD10 diagnosis code range
    C50.511-C50.519ICD10 diagnosis code range
    C50-611-C50.619ICD10 diagnosis code range
    C50.811-C50.819ICD10 diagnosis code range
    C50.911-C50.919ICD10 diagnosis code range
    1–10 of 18
    1/2
    HCSPCS CodeHCPCSCovered
    J9306Perjeta (pertuzumab) injection
    Availability NDCNDCCovered
    50242-0145-01Perjeta (pertuzumab) 420 mg/14 mL (30 mg/mL) single-dose vial containing preservative-free solution

    Clinical Background

    Perjeta (pertuzumab) is a HER2-directed therapy used in combination with trastuzumab and chemotherapy-based regimens for HER2-positive breast cancer. Covered uses include metastatic disease, neoadjuvant treatment for locally advanced, inflammatory, or early-stage disease, and adjuvant treatment for early breast cancer at high risk of recurrence.